Abaxis Receives CLIA Waived Status For 6 Additional Analytes By FDA

On Wednesday, October 18, Abaxis, Inc., a manufacturer of portable blood analysis systems, revealed that the FDA granted waived status under CLIA regulations for six additional analytes, when those analytes are used in conjuction with the Piccolo point-of-care analyzer for the medical market. The analytes include: Amylase, Gamma Glutamyltransferase, Total Bilirubin, and Total Protein. The company noted that including the six analytes, it now has a total of 12 analytes that have received the...
;